INTRODUCTION
============

*BRCA1* and *BRCA2* are tumor suppressor genes that are involved in multiple cellular processes, including DNA damage repair, cell cycle control, and transcription \[[@B1][@B2]\]. These processes perform universally essential functions in the homeostasis of all mammalian cells. However, the prevalence of *BRCA1/2* (*BRCA1* or *BRCA2*) mutation-related cancers is not similar across various organs \[[@B3]\]. Carriers of germline mutations of *BRCA1* and *BRCA2* are more likely to develop cancers of the breast and ovary, followed by those of the colon and prostate, with lesser incidence \[[@B4]\]. Breast and ovarian cancers are known to be regulated by sex hormones; thus, it is possible that *BRCA1/2* may be important regulators of growth and differentiation in hormonally responsive epithelial cells.

*BRCA1* can regulate the estrogen receptor (ER)-mediated downstream signaling by inhibiting transcriptional activators, such as activation function 2 (AF-2) \[[@B5]\] and p300 \[[@B6]\]. Further, mutations in the *BRCA1* gene can lead to increased vascular endothelial growth factor secretion and breast epithelial proliferation, via direct interaction between *BRCA1* and the ER protein \[[@B7]\].

As several studies have highlighted the potential interactions between the *BRCA1/2* genes and the ER in developing breast cancers, we hypothesized that the reproductive histories of women who are *BRCA1/2* mutation carriers can influence the clinical presentation of their breast cancer. To address this issue, we investigated the relationship between reproductive factors and the clinical characteristics of breast cancers in Korean women with germline mutations in *BRCA1* and *BRCA2*.

METHODS
=======

This study was conducted on women with either proven *BRCA1/2* mutations, or both, who were recruited to the Korean Hereditary Breast Cancer (KOHBRA) study, from 2007 to 2014. The study design and eligibility criteria have been described in a previously published KOHBRA interim report \[[@B8]\]. All probands received genetic counseling, and the genetic testing for the *BRCA* mutations was performed after obtaining informed consent. For this study, genetic mutations were narrowly defined as protein-truncating and missense mutations. Unclassified variants were not considered as genetic mutations. After extracting the genomic DNA from peripheral blood, genetic testing was carried out using three methods: fluorescence-based conformation sensitive gel electrophoresis, denaturing high performance liquid chromatography, and direct sequencing. *BRCA1/2* mutation testing was conducted by four DNA testing laboratories; all these laboratories are certified annually by the Korean Institute of Genetic Testing Evaluation. Each participating centre was linked to one of four DNA testing laboratories.

In this study, parous women were defined as women with one or more full-term pregnancies. For this analysis, the requirement to obtain separate consents was waived by the Institutional Review Board of Seoul National University Hospital (IRB number: 1511-010-714).

Statistical analysis
--------------------

We retrospectively analyzed women who carried either the *BRCA1* or the *BRCA2* mutation. *BRCA1* and *BRCA2* mutation carriers were separately analyzed. To assess the association between the reproductive factors of the *BRCA* mutation carriers and breast cancer, we used a cohort study design to compare women with *BRCA* mutations who developed breast cancers with those that did not. Continuous variables were compared using the Student t-test, and categorical variables were compared using the chi-square tests. Hazard ratios (HR) and 95% confidence intervals were calculated using the logistic regression test. All analyses were carried out using SPSS version 19.0 (IBM Corp., Armonk, USA). Values of *p*\<0.05 were deemed statistically significant.

RESULTS
=======

The present retrospective analyses were conducted on a cohort of 739 women with either proven *BRCA1* or *BRCA2* mutations, or both, who were registered in the KOHBRA study. Among these, three women for whom reproductive histories were unavailable were excluded from the present analysis. There were 284 women with the *BRCA1* germline mutation, 445 with the *BRCA2* mutation, and seven, who had mutations in both *BRCA1* and *BRCA2*. The characteristics of the entire study cohort and the distribution of reproductive factors among them are presented in [Table 1](#T1){ref-type="table"}.

The effect of reproductive factors on the development of breast cancers in women with the BRCA mutations
--------------------------------------------------------------------------------------------------------

Among the 736 women, a total of 483 had developed breast cancers at the time of their interview. Characteristics of the women with or without breast cancers are listed in [Table 2](#T2){ref-type="table"}. There were no differences in the risks of breast cancer in these women, based on their regularity and cycles of menstruation. Compared with parous women, nulliparous women were significantly associated with women who did not develop breast cancers, and this association was also observed in the subgroup with *BRCA1/2* mutations. However, except in the nulliparous women, the number of full-term pregnancies was lesser in women with breast cancers than in those who did not develop breast cancer, in the group with the *BRCA1* mutation (1.87±0.77 vs. 2.44±1.26, *p*=0.002). The age of first childbirth was not associated with the risks of developing breast cancer.

In this study, the mean age of diagnosis of breast cancer in all patients was 39.0 years; in women with the *BRCA1* mutation, 38.01±8.31 years, and in women with the *BRCA2* mutation, 42.36±10.04 years. The age at menarche and the parity were significantly associated with the age of diagnosis. Women who experienced menarche at 14 years of age or earlier were diagnosed with breast cancer at younger ages than women who experienced menarche at over 14 years of age (37.38±7.60 and 43.30±10.11 years, respectively, *p*\<0.001). Additionally, the number of full-term pregnancies was significantly associated with the age of diagnosis, especially in women with the *BRCA2* mutation (*p*\<0.001) ([Figure 1](#F1){ref-type="fig"}). However, the regularity and cycles of menstruation were not significant ([Table 3](#T3){ref-type="table"}).

Differences in breast cancer stage according to the reproductive factors
------------------------------------------------------------------------

Among 483 patients with breast cancers, 27 had *in situ* cancers, 391 had stage I--III disease, and 65 had unknown status. We examined the association between the reproductive factors and breast cancer stage. Our analysis showed that the number of parous events was significantly associated with the risk of advanced disease (stage II or III vs. stage I). In all patients, the prevalence of the advanced stage was higher in parous women than in nulliparous women (68.5% vs. 55.2%, *p*=0.043). The association was more pronounced in women with the *BRCA2* mutation (HR, 2.67; *p*=0.014) ([Table 4](#T4){ref-type="table"}). With increase in the numbers of full-term pregnancies, the probability of developing advanced breast cancers was higher in parous women than in nulliparous women, in the group with the *BRCA2* mutation ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, available online).

DISCUSSION
==========

As the *BRCA* proteins are known to play protective roles against the carcinogenic effects of estradiol \[[@B5][@B6][@B7]\], we hypothesized that the factors influencing the duration of the reproductive period may affect the characteristics of breast cancer presentation in carriers of the *BRCA1* and *BRCA2* mutations. In accordance with our hypothesis, we observed that younger age at menarche and nulliparity were strongly associated with early onset of breast cancer. However, our analysis also revealed an unexpected finding that breast cancers in *BRCA2* mutation carriers who had early onset of menarche or who were nulliparous were more likely to have early-stage tumors. Bayraktar et al. \[[@B9]\] have reported that late menarche in *BRCA1* mutation carriers was associated with advanced stages of breast cancer; in a population-based study, Alsaker et al. \[[@B10]\] reported worse outcomes for breast cancer in women with higher numbers of parous events. In our study, we observed that as the numbers of full-term pregnancies increased, the probability of advanced breast cancers in parous women was higher than the probability in nulliparous women, in the group with the *BRCA2* mutation.

The control of cell proliferation is stimulated by increased levels of estrogen during puberty, and especially before the first birth, but may be dysregulated in breast cells that harbor *BRCA1/2* mutations \[[@B2][@B11]\]. However, the different effects of reproductive factors on breast cancer characteristics in the carriers of the *BRCA1* and *BRCA2* mutations suggest that responses to hormones may differ between them. A good example of these differences is the fact that only 10% to 24% of *BRCA1*-associated breast cancers are ER-positive, whereas 65% to 79% of *BRCA2*-associated breast cancers are ER-positive \[[@B12][@B13]\]. In our study, the age of breast cancer diagnosis was higher in patients with the *BRCA2* mutation patients than in those with the *BRCA1* mutation, and the effect of reproductive factors on surgical stage was pronounced only in women with the *BRCA2* mutation.

Regarding the onset of breast cancer in patients, we found that higher number of parous events and late age of menarche had a protective effect, but this protection may be limited in the number of years. In a recent study, longer time intervals between age at first pregnancy and at breast cancer diagnosis reduced the breast cancer mortalities in premenopausal women \[[@B14]\]. A similar study also found that high parity may have a protective effect against small and low-grade tumors \[[@B15][@B16]\]; consequently, women with high parity may have relatively advanced and more aggressive disease. Additionally, this protective effect of parity may be limited only to ER-positive tumors \[[@B17]\]; however, it has been suggested that high parity may also increase the risks for triple-negative breast cancer \[[@B18]\].

Pregnancy and childbirth have been shown to be protective factors in terms of the lifetime risk of breast cancer in the general population. However, in *BRCA* mutation carriers, the results from previous studies of the effect of parity on breast cancer have varied. Milne et al. \[[@B19]\] reported that parity was associated with protection from breast cancers in *BRCA1* and *BRCA2* mutation carriers, and each live-birth was associated with an estimated 13% risk reduction. On the other hand, a study based on 55 international collaborating centers \[[@B20]\] observed that increasing parity was associated with increased risk of breast cancer (15% per live-birth) in women who were *BRCA2* carriers. In a recent meta-analysis, the risks of breast cancer in parous women who were *BRCA1/2* mutation carriers were not statistically different from the risks in corresponding nulliparous women. Additionally, the risks of breast cancer associated with increasing parity were not significantly reduced \[[@B21]\].

Our study has several limitations. First, our results are based on retrospective data obtained from women who opted for genetic testing for the *BRCA1* and *BRCA2* mutations. Thus, other factors, such as psychological status or memorial ability, might have influenced the results of the study. Additionally, well-known lifestyle factors, including obesity and alcohol consumption, could have introduced a bias in the results. Second, data on reproductive factors were not available for all women who were *BRCA* mutation carriers. Third, the relationship between the regularity of menstruation and breast cancer in *BRCA* mutation carriers was not properly examined. Although most women in this study believed that they had regular cycles of menstruation, the meaning of "regular" may differ among individuals.

This study showed the differential risks of breast cancer associated with reproductive factors in women who were *BRCA1/2* mutation carriers. Early menarche and nulliparity were associated with earlier onset of breast cancers in women who were *BRCA1/2* mutation carriers. However, parity was associated with more advanced stage at presentation, especially in women who were *BRCA2* mutation carriers. Our observations need further testing with longitudinal follow-up data, in a larger cohort of women who are *BRCA1/2* mutation carriers.
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###### Supplementary Table 1

The risk for the advanced breast cancer according to number of full term pregnancy

![Bar plot with 95% confidence interval of diagnosed age of breast cancer according to number of full-term pregnancy. Diagnosed age of breast cancer was increased according to the number of full-term pregnancy. (A) All patients, *p*\<0.001; (B) *BRCA1* mutation group, *p*=0.234; and (C) *BRCA2* mutation group, *p*\<0.001.](jbc-20-279-g001){#F1}

###### Characteristics of the study group

![](jbc-20-279-i001)

  Characteristic                      Mutation carried                 
  ----------------------------------- ------------------ ------------- ------------
  Age at test of mutations (yr)^\*^   42.20±11.62        42.18±12.53   39.67±7.74
  Age of menarche (yr)\*              14.30±1.61         14.77±1.75    15.29±2.21
   ≤14                                142 (50.0)         175 (39.3)    1 (14.3)
   \>14                               110 (38.7)         202 (45.4)    6 (85.7)
   Unknown                            32 (11.3)          68 (15.3)     0
  Parity                                                               
   Nulliparous                        83 (29.2)          135 (30.3)    2 (28.6)
   Parous                             161 (56.7)         258 (58.0)    4 (57.1)
   Unknown                            40 (14.1)          52 (11.7)     1 (14.3)
  No. of full-term pregnancy^\*^      1.33±1.20          1.34±1.25     1.17±0.98
  Age at first birth (yr)^\*^         26.82±3.98         26.28±3.27    25.25±4.65
   \<30                               130 (45.7)         222 (49.9)    3 (42.9)
   ≥30                                34 (12.0)          37 (8.3)      1 (14.2)
   Unknown                            120 (42.3)         186 (41.8)    3 (42.9)
  Regularity of menstruation                                           
   Regular                            219 (77.1)         313 (70.3)    7 (100)
   Irregular                          34 (12.0)          65 (14.6)     0
   Unknown                            31 (10.9)          67 (15.1)     0
  Cycle of menstruation (day)                                          
   ≤28                                141 (49.6)         194 (43.6)    4 (57.1)
   \>28                               103 (36.3)         164 (36.9)    3 (42.9)
   Unknown                            40 (14.1)          87 (19.5)     0
  Patient with breast cancer          195 (68.9)         282 (63.3)    7 (100)
   ER and/or PR (+)                   65 (33.3)          185 (65.6)    5 (71.4)
   ER and PR (-)                      106 (54.4)         59 (20.9)     1 (14.3)
   Unknown                            24 (12.3)          38 (13.5)     1 (14.3)
  Patients with any cancers           204 (72.1)         291 (65.5)    7 (100)

ER=estrogen receptor; PR=progesterone receptor.

^\*^Mean±SD.

###### Reproductive factors and breast cancer risk among mutation carriers

![](jbc-20-279-i002)

  Characteristic                      All patients    *BRCA1* mutation patients   *BRCA2* mutation patients                                                                               
  ----------------------------------- --------------- --------------------------- --------------------------- --------------- --------------- ----------- --------------- --------------- ----------
  Age at test of mutations (yr)^\*^   42.61 ± 11.01   41.42 ± 14.05               0.243                       42.50 ± 10.00   41.84 ± 14.51   0.707       42.81 ± 11.61   41.18 ± 13.83   0.214
  Age of menarche (yr)^\*^            14.58 ± 1.78    14.71 ± 1.73                0.454                       14.36 ± 1.82    14.73 ± 1.76    0.221       14.81 ± 1.78    14.70 ± 1.72    0.620
   ≤ 14                               230 (48.9)      89 (53.0)                   0.419                       80 (52.39)      36 (60.0)       0.360       111 (44.9)      53 (49.1)       0.489
   \> 14                              240 (51.1)      79 (47.0)                                               73 (47.7)       24 (40.0)                   136 (55.1)      55 (50.9)       
  Parity                                                                          \< 0.001                                                    \< 0.001                                    \< 0.001
   Nulliparous                        77 (19.1)       143 (59.3)                  25 (19.8)                   35 (41.2)       39 (18.2)       93 (59.6)                                   
   Parous                             327 (80.9)      98 (40.7)                   101 (80.2)                  50 (58.8)       175 (81.8)      63 (40.4)                                   
  No. of full-term pregnancy^†^       2.00 ± 0.92     2.14 ± 1.00                 0.215                       1.87 ± 0.77     2.44 ± 1.26     0.002       2.06 ± 0.92     1.97 ± 0.79     0.494
  Age at first birth (yr)^\*^         26.60 ± 3.53    25.98 ± 3.53                0.131                       27.26 ± 3.53    26.03 ± 3.53    0.118       26.24 ± 3.53    25.95 ± 3.53    0.547
   \< 30                              275 (82.8)      82 (84.5)                   0.759                       79 (76.7)       28 (82.4)       0.634       155 (87.6)      54 (85.7)       0.668
   ≥ 30                               57 (17.2)       15 (15.5)                                               24 (23.3)       6 (17.6)                    22 (12.4)       9 (14.3)        
  Regularity of menstruation                                                      0.173                                                       0.646                                       0.044
   Regular                            404 (85.6)      136 (81.0)                  134 (87.0)                  54 (90.0)       209 (84.3)      82 (75.9)                                   
   Irregular                          68 (14.4)       32 (19.0)                   20 (13.0)                   6 (10.0)        39 (15.7)       26 (24.1)                                   
  Cycle of menstruation (day)                                                     0.643                                                       0.552                                       0.552
   ≤ 28                               253 (56.2)      86 (53.8)                   128 (54.9)                  52 (51.0)       128 (54.9)      52 (51.0)                                   
   \> 28                              197 (43.8)      74 (46.3)                   105 (45.1)                  50 (49.0)       105 (45.1)      50 (49.0)                                   

^\*^Mean±SD; ^†^Except to nulliparous.

###### Diagnosed age of breast cancer according to reproductive factors

![](jbc-20-279-i003)

  Characteristic                All patients   *BRCA1* mutation patients   *BRCA2* mutation patients                                                                                             
  ----------------------------- -------------- --------------------------- --------------------------- -------------- ----- --------------- ----------------- ---------- -- -- ----------------- ----------
  Age of menarche (yr)                                                     4.29 to 7.54                \< 0.001                             −6.71 to -2.01    \< 0.001         -8.85 to -4.50    \< 0.001
   ≤ 14                         230            37.38 ± 7.60                106                         36.12 ± 7.07   123   38.57 ± 7.84                                                         
   \> 14                        240            43.30 ± 10.11               87                          40.48 ± 9.04   147   45.24 ± 10.30                                                        
  Parity                                                                   5.83 to 10.12               \< 0.001                             -10.73 to -5.32   \< 0.001         −11.18 to -4.76   \< 0.001
   Nulliparous                  77             33.85 ± 8.42                33                          31.52 ± 6.51   42    35.48 ± 9.46                                                         
   Parous                       332            41.83 ± 9.13                131                         39.54 ± 8.32   197   43.44 ± 9.29                                                         
  Age at first birth (yr)                                                  −0.38 to 4.81               0.094                                −2.78 to 4.21     0.685            −1.24 to 6.20     0.190
   \< 30                        275            42.20 ± 9.33                103                         39.61 ± 8.34   169   43.88 ± 9.52                                                         
   ≥ 30                         57             39.98 ± 7.76                28                          38.89 ± 8.08   28    41.39 ± 7.29                                                         
  Regularity of menstruation                                               −2.19 to 2.69               0.837                                −4.04 to 2.64     0.681            −2.18 to 4.47     0.500
   Regular                      404            40.47 ± 9.42                166                         37.98 ± 8.00   231   42.44 ± 9.92                                                         
   Irregular                    68             40.22 ± 9.70                28                          38.68 ± 9.85   40    41.30 ± 9.58                                                         
  Cycle of menstruation (day)                                              −2.14 to 1.33               0.650                                −2.44 to 2.41     0.990            −3.04 to 1.72     0.587
   ≤ 28                         253            40.20 ± 8.69                107                         38.15 ± 8.06   142   41.84 ± 8.85                                                         
   \> 28                        197            40.60 ± 10.02               79                          38.16 ± 8.58   115   42.50 ± 10.54                                                        

CI=confidence interval.

###### Reproductive factors in relation to stage II and III versus to stage I of breast cancer

![](jbc-20-279-i004)

  Characteristic                All patients   *BRCA1* mutation patients   *BRCA2* mutation patients                                                                                                 
  ----------------------------- -------------- --------------------------- --------------------------- ------------ ----------- ------ ----- ------------ ------------ ------- -- -- -- ------------ -------
  Age of menarche (yr)                                                                                 1.00--2.33   0.053                                 0.63--2.36   0.564            1.01--3.14   0.044
   ≤ 14                         195            122 (62.6)                  1                           91           58 (63.7)   1      103   63 (61.2)    1                                          
   \> 14                        195            140 (71.8)                  1.52                        69           47 (68.1)   1.22   122   90 (73.8)    1.79                                       
  Parity                                                                                               1.04--3.09   0.037                                 0.51--2.69   0.702            1.14--5.15   0.021
   Nulliparous                  67             37 (55.2)                   1                           31           19 (61.3)   1      34    17 (50.0)    1                                          
   Parous                       266            183 (68.8)                  1.79                        103          67 (65.0)   1.18   161   114 (70.8)   2.43                                       
  Age at first birth (yr)                                                                              0.51--2.03   0.847                                 0.35--2.50   0.901            0.45--3.31   0.690
   \< 30                        223            154 (69.1)                  1                           83           54 (65.1)   1      138   98 (71.0)    1                                          
   ≥ 30                         46             32 (69.6)                   1.02                        22           14 (63.6)   0.94   24    18 (75.0)    1.22                                       
  Regularity of menstruation                                                                           0.55--1.81   0.988                                 0.36--2.36   0.867            0.49--2.30   0.889
   Regular                      334            223 (66.8)                  1                           139          91 (65.5)   1      190   128 (67.4)   1                                          
   Irregular                    57             38 (66.7)                   0.99                        22           14 (63.6)   0.92   35    24 (68.6)    1.06                                       
  Cycle of menstruation (day)                                                                          0.74--1.77   0.535                                 0.56--2.11   0.815            0.67--2.12   0.548
   ≤ 28                         207            135 (65.2)                  1                           87           56 (64.4)   1      116   76 (65.5)    1                                          
   \> 28                        167            114 (68.3)                  1.15                        68           45 (66.2)   1.08   98    68 (69.4)    1.19                                       

Adv. stage=advanced stage; HR=hazard ratio; CI=confidence interval.

[^1]: ^\*^These authors contributed equally to this work.
